JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Jade Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$13.83+0.36 (+2.67%)

Close on Oct 19, 2026

Market cap: $844.33M
P/E (TTM): –
Dividend yield: –

Jade Biosciences, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Stock-Based Compensation	20	11	12	5.48	2.04	0.06
Deferred Income Taxes	-0.04	–	–	–	–	–
Change in Accounts Payable	0.36	-2.17	-0.16	1.37	0.61	0.04
Operating Cash Flow	-95	-71	-57	-39	-27	-7.86
Capital Expenditures	-0.20	–	-0.14	-0.20	-0.18	–
Purchase of Investments	-261	-20	-124	-148	-113	–
Sale & Maturity of Investments	14	–	–	–	–	–
Investing Cash Flow	-247	56	12	6.93	-113	–
Stock Issued	–	24	45	–	127	–
Other Financing Activities	189	–	–	–	–	–
Financing Cash Flow	361	25	46	0.40	190	8.92
Foreign Exchange Rate Adjustments	-0.02	–	–	–	–	–
Net Change in Cash	19	10	1.09	-32	50	1.06
Free Cash Flow	-95	–	-57	-39	-28	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -89.2%

Financial strength

Current ratio: 14.93
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 339.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.92
Dividend yield: –